<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Progestogens: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int664-progestogens.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int664-progestogens.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int664-progestogens.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int663-probenecid.htm" title="Previous: Probenecid">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1172-dienogest.htm" title="Next: Dienogest">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Progestogens</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Progestogens</strong> has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int264-antidiabetics.htm">Antidiabetics</a></td><td><p><span></span> <span>progestogens</span> <span>antagonise hypoglycaemic effect of</span> <span>antidiabetics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td class="cAI"><p><span>possible contraceptive failure of hormonal contraceptives containing </span> <span>progestogens</span> <span>when given with</span> <span>aprepitant</span> <span>(alternative contraception recommended)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td class="cAI"><p><span>possible contraceptive failure of hormonal contraceptives containing </span> <span>progestogens</span> <span>when given with</span> <span>bosentan</span> <span>(alternative contraception recommended)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>metabolism of </span> <span>progestogens</span> <span>accelerated by</span> <span>carbamazepine</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span></span> <span>progestogens</span> <span>possibly increase plasma concentration of</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td><p><span></span> <span>progestogens</span> <span>may enhance or reduce anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int412-diazepam.htm">Diazepam</a></td><td><p><span></span> <span>progestogens</span> <span>possibly increase plasma concentration of</span> <span>diazepam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td class="cAI"><p><span>contraceptive effect of </span> <span>progestogens</span> <span>possibly reduced by</span> <span>efavirenz</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1153-eslicarbazepine.htm">Eslicarbazepine</a></td><td class="cAI"><p><span>metabolism of </span> <span>progestogens</span> <span>accelerated by</span> <span>eslicarbazepine</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int291-griseofulvin.htm">Griseofulvin</a></td><td><p><span>anecdotal reports of contraceptive failure and menstrual irregularities when </span> <span>progestogens</span> <span>given with</span> <span>griseofulvin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td><p><span>contraceptive effect of </span> <span>progestogens</span> <span>possibly reduced by</span> <span>nelfinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td class="cAI"><p><span>metabolism of </span> <span>progestogens</span> <span>accelerated by</span> <span>nevirapine</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int900-oxcarbazepine.htm">Oxcarbazepine</a></td><td class="cAI"><p><span>metabolism of </span> <span>progestogens</span> <span>accelerated by</span> <span>oxcarbazepine</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td class="cAI"><p><span></span> <span>progestogens</span> <span>antagonise anticoagulant effect of</span> <span>phenindione</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>metabolism of </span> <span>progestogens</span> <span>accelerated by</span> <span>phenobarbital</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>metabolism of </span> <span>progestogens</span> <span>accelerated by</span> <span>phenytoin</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int199-rifamycins.htm">Rifamycins</a></td><td class="cAI"><p><span>metabolism of </span> <span>progestogens</span> <span>accelerated by</span> <span>rifamycins</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to rifaximin</p></div></td></tr><tr><td><a href="bnf_int1102-rufinamide.htm">Rufinamide</a></td><td class="cAI"><p><span>metabolism of </span> <span>progestogens</span> <span>accelerated by</span> <span>rufinamide</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span></span> <span>progestogens</span> <span>increase plasma concentration of</span> <span>selegiline</span> <span>—manufacturer of <span>selegiline</span> advises avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>contraceptive effect of </span> <span>progestogens</span> <span>reduced by</span> <span>St John's wort</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1127-sugammadex.htm">Sugammadex</a></td><td><p><span>plasma concentration of </span> <span>progestogens</span> <span>possibly reduced by</span> <span>sugammadex</span> <span>—manufacturer of <span>sugammadex</span> advises additional contraceptive precautions</span>  </p></td><td></td></tr><tr><td><a href="bnf_int292-terbinafine.htm">Terbinafine</a></td><td><p><span>occasional reports of breakthrough bleeding when </span> <span>progestogens</span> <span>(used for contraception) given with</span> <span>terbinafine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int805-tizanidine.htm">Tizanidine</a></td><td><p><span></span> <span>progestogens</span> <span>possibly increase plasma concentration of</span> <span>tizanidine</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int285-topiramate.htm">Topiramate</a></td><td class="cAI"><p><span>metabolism of </span> <span>progestogens</span> <span>accelerated by</span> <span>topiramate</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1163-ulipristal.htm">Ulipristal</a></td><td class="cAI"><p><span>contraceptive effect of </span> <span>progestogens</span> <span>possibly reduced by</span> <span>ulipristal</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1229-vemurafenib.htm">Vemurafenib</a></td><td class="cAI"><p><span>possible reduction in contraceptive effect of </span> <span>progestogens</span> <span>advised by manufacturer of</span> <span>vemurafenib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td><p><span></span> <span>progestogens</span> <span>possibly increase plasma concentration of</span> <span>voriconazole</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Dienogest</strong> belongs to <strong>Progestogens</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>plasma concentration of </span> <span>dienogest</span> <span>increased by</span> <span>erythromycin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr></tbody></table><p><strong>Norelgestromin</strong> belongs to <strong>Progestogens</strong> but has no specific interaction information.</p><p><strong>Drospirenone</strong> belongs to <strong>Progestogens</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td><p><span>plasma concentration of </span> <span>drospirenone</span> <span>increased by</span> <span>boceprevir</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int544-diuretics-potassium-sparing-and-aldosterone-antagonists.htm">Diuretics, Potassium-sparing and Aldosterone Antagonists</a></td><td><p><span>risk of hyperkalaemia when </span> <span>drospirenone</span> <span>given with</span> <span>potassium-sparing diuretics and aldosterone antagonists</span> <span>(monitor serum potassium during first cycle)</span>  </p></td><td></td></tr></tbody></table><p><strong>Desogestrel</strong> belongs to <strong>Progestogens</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int283-lamotrigine.htm">Lamotrigine</a></td><td><p><span></span> <span>desogestrel</span> <span>possibly increases plasma concentration of</span> <span>lamotrigine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Dydrogesterone</strong> belongs to <strong>Progestogens</strong> but has no specific interaction information.</p><p><strong>Etonogestrel</strong> belongs to <strong>Progestogens</strong> but has no specific interaction information.</p><p><strong>Etynodiol</strong> belongs to <strong>Progestogens</strong> but has no specific interaction information.</p><p><strong>Gestodene</strong> belongs to <strong>Progestogens</strong> but has no specific interaction information.</p><p><strong>Levonorgestrel</strong> belongs to <strong>Progestogens</strong> but has no specific interaction information.</p><p><strong>Medroxyprogesterone</strong> belongs to <strong>Progestogens</strong> but has no specific interaction information.</p><p><strong>Megestrol</strong> belongs to <strong>Progestogens</strong> but has no specific interaction information.</p><p><strong>Norethisterone</strong> belongs to <strong>Progestogens</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td><p><span>plasma concentration of </span> <span>norethisterone</span> <span>increased by</span> <span>atazanavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>plasma concentration of </span> <span>norethisterone</span> <span>increased by</span> <span>atorvastatin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Norgestimate</strong> belongs to <strong>Progestogens</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td><p><span>plasma concentration of active metabolite of </span> <span>norgestimate</span> <span>increased by</span> <span>rosuvastatin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Norgestrel</strong> belongs to <strong>Progestogens</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td><p><span>plasma concentration of </span> <span>norgestrel</span> <span>increased by</span> <span>rosuvastatin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Progesterone</strong> belongs to <strong>Progestogens</strong> but has no specific interaction information.</p></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int1172-dienogest.htm" title="Dienogest">Dienogest</a></li><li><a href="bnf_int972-norelgestromin.htm" title="Norelgestromin">Norelgestromin</a></li><li><a href="bnf_int962-drospirenone.htm" title="Drospirenone">Drospirenone</a></li><li><a href="bnf_int665-desogestrel.htm" title="Desogestrel">Desogestrel</a></li><li><a href="bnf_int666-dydrogesterone.htm" title="Dydrogesterone">Dydrogesterone</a></li><li><a href="bnf_int890-etonogestrel.htm" title="Etonogestrel">Etonogestrel</a></li><li><a href="bnf_int667-etynodiol.htm" title="Etynodiol">Etynodiol</a></li><li><a href="bnf_int668-gestodene.htm" title="Gestodene">Gestodene</a></li><li><a href="bnf_int671-levonorgestrel.htm" title="Levonorgestrel">Levonorgestrel</a></li><li><a href="bnf_int672-medroxyprogesterone.htm" title="Medroxyprogesterone">Medroxyprogesterone</a></li><li><a href="bnf_int801-megestrol.htm" title="Megestrol">Megestrol</a></li><li><a href="bnf_int673-norethisterone.htm" title="Norethisterone">Norethisterone</a></li><li><a href="bnf_int674-norgestimate.htm" title="Norgestimate">Norgestimate</a></li><li><a href="bnf_int675-norgestrel.htm" title="Norgestrel">Norgestrel</a></li><li><a href="bnf_int837-progesterone.htm" title="Progesterone">Progesterone</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int663-probenecid.htm">Previous: Probenecid</a> | <a class="top" href="bnf_int664-progestogens.htm#">Top</a> | <a accesskey="]" href="bnf_int1172-dienogest.htm">Next: Dienogest</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>